Lutetium-177 treatment for advanced neuroendocrine tumors
Part of Cancer clinical trials.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older (or between 12-17 and weigh at least 88 lbs).
- You have an advanced neuroendocrine tumor that is not a well-differentiated gastrointestinal or pancreas NET, and your doctor has confirmed this with a biopsy.
- You have tried standard treatments (like chemotherapy or targeted therapy) and either they didn't work, you couldn't handle the side effects, or you can't get them.
- Your tumor has grown or spread in the past year, and you haven't had any other cancer treatment since then.
- You have at least one tumor that can be measured on a scan, and a special PET scan (68Ga-Dotatate) showed your tumors are positive for somatostatin receptors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
This study looks at outcomes for adults with tumors that are advanced (can’t be fully removed or has spread) and are getting worse, where tests show somatostatin receptors. It aims to understand how treatment with lutetium-177 helps people in this situation.
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
Hear when a new Advanced Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.